CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Researchers from Skoltech—a VEB.RF group institution—and their colleagues from the U.S. and China have explained how the ...

When the genome-editing tool CRISPR is thought of as a potential medicine, the targets that first come to mind are diseases like sickle cell or other conditions caused by particular mutations. Use ...

Last month, CRSP reported initial top-line results from an early-stage study on CTX310, its investigational in vivo CRISPR-based gene therapy, designed to target ANGPTL3 for the treatment of ...

Imagine being able to edit the genetic code that causes diseases like sickle cell anemia, certain cancers, or inherited blindness. That is not science fiction anymore. It is the working reality of ...

Researchers have been able to manipulate large chunks of genetic code for almost 50 years. But it is only within the past decade that they have been able to do it with exquisite precision – adding, ...

Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer. As researchers have learned more and more about the cancer-immune system interplay, ...

CRISPR screens generate actionable insights for drug discovery—explore how to optimize a screen, how to avoid pitfalls, and ...

Scientists recently slashed high cholesterol levels by 62 percent.

In 2020, Jennifer Doudna won the Nobel Prize in chemistry for her work on the CRISPR-Cas9 gene-editing technology that allows ...